contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  availableLanguages
  pageUrl
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


ascelia-pharma-wrap-up-from-interview-with-deputy-ceo-julia-waras-brogren

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

availableLanguages

pageUrl

imgUrl

description

CEO, Sweden

Claus Thestrup

Equity Research Analyst

Henrik Ekman

Ascelia Pharma är ett läkemedelsbolag. Bolaget är specialiserat på utveckling av särläkemedel inom onkologi (cancer). Bolaget utvecklar diverse läkemedelskandidater, där störst användning återfinns inom behandling av cancer som drabbat lever och magsäck. Bolaget grundades år 2000 och har huvudkontor i Malmö, Sverige, men är verksamt på en global marknad.

Ascelia Pharma

What does launch readiness implies? and What qualities should a partner have to match Ascelia Pharma's strategy 

Ascelia Pharma participated in an event with HCA Capital on Monday June 17th to discuss its future partner strategy and how to launch Orviglance once it has been approved. At the event Deputy CEO Julie Waras Brogren once again made a thorough and confident presentation signaling that the company remains on track and are well prepared to submit the regulatory application (NDA) for an FDA approval of Orviglance by mid 2025 based on the full data from the completed phase 3 SPARKLE study as these data become available in the 4th quarter of 2024.
At the event, Julie Waras Brogren explained that at this point in the submission preparation process, Ascelia Pharma has all the necessary competencies allocated to the regulatory application and that the company has the time and flexibility to find the right partner and doesn&#x2019;t need a partner to prepare and make the regulatory submission. Importantly, Ascelia Pharma also explained that the company has fully compliant, high quality and scalable manufacturing in place already.
With regards to finding the right partner, among other things, Julie Waras Brogren described the de-risked nature of the commercial opportunity for Orviglance as being one of the most important features. For example, clinical development for Orviglance has been completed with strong efficacy and safety results, including in the Phase 3 study. A clear unmet need and validation through extensive market research and data is in place, suggesting an attractive proposition and high &#x2018;launch readiness&#x2019; for a potential partner.
To see the whole interview and further comments on the balance between up front milestones versus royalty-based partnerships etc.
Watch full interview here: <a href="https://www.youtube.com/watch?v=u9ycFdeqeoM" target="_blank" rel="noopener">Interview with Julie Waras Brogren</a>
Disclaimer: HC Andersen Capital receives payment from Ascelia Pharma for a Digital IR/Corporate Visibility subscription agreement. /Claus Thestrup 10:45 AM 18-06-2024
<div style="mso-element: comment-list"><hr class="msocomoff" align="left" size="1" width="33%">
<div style="mso-element: comment">
<div id="_com_1" class="msocomtxt"><a name="_msocom_1"></a>
&#xa0;
</div>
</div>
</div>

Ascelia Pharma: Wrap up from interview with Deputy CEO Julia Waras Brogren

Login required

Ascelia Pharma

Login required

Ascelia Pharma

Beställ vårt nyhetsbrev — inget användarkonto krävs!